http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 03:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/Press+Releases/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>June 3, 2026</chron></span> /PRNewswire/ -- Global pharma major <span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) and its alliance partner Natco Pharma Limited (Natco) today announced the approval from the <span>United States Food and Drug Administration</span> (<location value="LC/us" idsrc="xmltag.org" >U.S</location>. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.</p> <div id="prni_dvprnejpgbc87left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgbc87left" style="width: 331px; height: 400px;" title="Lupin Logo" src="https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg" alt="Lupin Logo" align="middle" /></div><p>Eribulin Mesylate Injection, 1 http://www.streetinsider.com/PRNewswire/Lupin+and+Natco+Receive+Approval+from+U.S.+FDA+for+Eribulin+Mesylate+Injection/26594306.html Wed, 03 Jun 2026 03:11:00 -0400 500257 500257 A.01721546 A.11820776 LUPIN LUPIN.BO LUPIN.NS O.00093063 O.01520983 O.03319887 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of Clinical Oncology Annual Meeting held May 29-June 2, 2026, in Chicago.</p> <p>The study evaluated LNP8701, an orally administered SOS1 inhibitor designed to block oncogenic signaling that promotes tumor growth, in patients with metastatic solid tumors. According to the company's statement, the drug demonstrated tolerability and safety across all tested dosing levels.</p> <p>The abstract, published in the Developmental Therapeutics track, reported that two patients completed 12 cycles of LNP8701 monotherapy and one patient completed 14 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html Thu, 28 May 2026 08:26:21 -0400 500257 A.01721546 A.50208902 A.50216726 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 REUTERS http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of Clinical Oncology Annual Meeting held May 29-June 2, 2026, in Chicago.</p> <p>The study evaluated LNP8701, an orally administered SOS1 inhibitor designed to block oncogenic signaling that promotes tumor growth, in patients with metastatic solid tumors. According to the company's statement, the drug demonstrated tolerability and safety across all tested dosing levels.</p> <p>The abstract, published in the Developmental Therapeutics track, reported that two patients completed 12 cycles of LNP8701 monotherapy and one patient completed 14 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html Thu, 28 May 2026 08:26:21 -0400 500257 A.01721546 A.50208902 A.50216726 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 REUTERS http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of Clinical Oncology Annual Meeting held May 29-June 2, 2026, in Chicago.</p> <p>The study evaluated LNP8701, an orally administered SOS1 inhibitor designed to block oncogenic signaling that promotes tumor growth, in patients with metastatic solid tumors. According to the company's statement, the drug demonstrated tolerability and safety across all tested dosing levels.</p> <p>The abstract, published in the Developmental Therapeutics track, reported that two patients completed 12 cycles of LNP8701 monotherapy and one patient completed 14 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html Thu, 28 May 2026 08:26:21 -0400 500257 A.01721546 A.50208902 A.50216726 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 REUTERS http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of Clinical Oncology Annual Meeting held May 29-June 2, 2026, in Chicago.</p> <p>The study evaluated LNP8701, an orally administered SOS1 inhibitor designed to block oncogenic signaling that promotes tumor growth, in patients with metastatic solid tumors. According to the company's statement, the drug demonstrated tolerability and safety across all tested dosing levels.</p> <p>The abstract, published in the Developmental Therapeutics track, reported that two patients completed 12 cycles of LNP8701 monotherapy and one patient completed 14 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html Thu, 28 May 2026 08:26:21 -0400 500257 A.01721546 A.50208902 A.50216726 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 REUTERS http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html <p>Lupin Limited (BSE: 500257, NSE: LUPIN) announced that results from its Phase 1a trial of LNP8701, an experimental cancer treatment, have been presented at the American Society of Clinical Oncology Annual Meeting held May 29-June 2, 2026, in Chicago.</p> <p>The study evaluated LNP8701, an orally administered SOS1 inhibitor designed to block oncogenic signaling that promotes tumor growth, in patients with metastatic solid tumors. According to the company's statement, the drug demonstrated tolerability and safety across all tested dosing levels.</p> <p>The abstract, published in the Developmental Therapeutics track, reported that two patients completed 12 cycles of LNP8701 monotherapy and one patient completed 14 http://www.streetinsider.com/FDA/Lupin+presents+phase+1+data+for+cancer+drug+LNP8701+at+ASCO+meeting/26561639.html Thu, 28 May 2026 08:26:21 -0400 500257 A.01721546 A.50208902 A.50216726 LUPIN LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 REUTERS